Jimmy O. Yang Upgrades His Vision With EVO
Actor and Stand-up Comedian
Actor and Stand-up Comedian
Jimmy O. Yang's Life-Changing Journey with EVO ICL
Jimmy O. Yang, the talented American actor, stand-up comedian, and writer, has always had a passion for entertainment and storytelling. But for years, he faced a common struggle shared by millions worldwide – the hassle of glasses and contact lenses. Discover how EVO Implantable Collamer® Lenses (ICL) changed his vision and his life, highlighting the life-changing benefits of this procedure in his own words.
The Inconvenience of Glasses and Contacts
Jimmy's vision correction journey began when he started wearing glasses at the age of 13. Over the years, the constant need to put on and take off his glasses had become an accepted part of his life. He tried contact lenses during college, but they never truly felt comfortable. For a while, Jimmy resigned himself to the inconveniences of glasses and contacts. Until he discovered EVO implantable lenses, a cutting-edge vision correction procedure that was “a good fit for my eyes and the perfect solution for me.”
The EVO ICL Difference
Jimmy's decision to choose EVO ICL was driven by several remarkable benefits that “made me feel safe with this option”:
- Minimally Invasive Procedure: EVO ICL offers a minimally invasive approach and a safe way to correct nearsightedness, with or without astigmatism.
- Quick Recovery: The procedure's quick recovery time impressed Jimmy, and he was back to his normal activities the next day.
- Effective Vision Correction: EVO ICL provided Jimmy with an excellent quality of vision1,2 without inducing dry eye syndrome3,4.
- Removability and Flexibility: The possibility that a doctor can remove the lenses and/or replace them in the future gave Jimmy peace of mind, knowing he has options.
Since undergoing the EVO ICL procedure, Jimmy's life has been transformed.
“It's made my life much easier. I don't have to worry about the hassle of constantly putting on and taking off my glasses, I can play basketball without worrying about contacts, I can swim and actually see the end of the swimming pool. And now I can finally wear cool sunglasses over my amazing eyeballs.”
In Jimmy's own words, his message to anyone on the fence about getting EVO ICL is simple:
"We're so used to wearing glasses and contacts that we sometimes forget how much of a hassle they are. EVO ICL has made my life much simpler, and if I ever want to throw on an old pair of glasses for looks, I still can, without having to pay for the expensive prescription."
If you're tired of the daily hassles of glasses and contacts, consider following in his footsteps and embrace a future with clear, sharp EVO-vision1,5, just like Jimmy.
References:
1. Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
2. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
3. Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.
4. Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid measurements as dry-eye score in patients after LASIK and ICL surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
5. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53.
Bạn đã sẵn sàng tìm hiểu Tự do về thị giác với EVO ICL chưa? Tìm bác sĩ ngay hôm nay
Thông tin an toàn quan trọng
Thông tin An toàn Quan trọng cho EVO/EVO+ ICL
Trước khi cân nhắc phẫu thuật EVO/EVO+ ICL, bạn nên khám mắt toàn diện và trao đổi với chuyên gia chăm sóc mắt của mình về quy trình EVO/EVO+ ICL, đặc biệt là những lợi ích, rủi ro và biến chứng tiềm ẩn. Bạn nên thảo luận về thời gian cần thiết để hồi phục sau phẫu thuật. EVO/EVO+ ICL được thiết kế để điều chỉnh/giảm tới -20 diop (D) cận thị và lên tới 6 D loạn thị cho bệnh nhân từ 21 đến 60 tuổi. Việc lắp đặt EVO/EVO+ ICL là một quy trình phẫu thuật và do đó, tiềm ẩn những rủi ro nghiêm trọng. Sau đây là các biến chứng/sự cố bất lợi có thể xảy ra: cần thêm một cuộc phẫu thuật, hình thành đục thủy tinh thể, mất thị lực điều chỉnh tốt nhất thoáng qua hoặc kéo dài, tăng áp lực nội nhãn, mất tế bào nội mô giác mạc, kích ứng kết mạc, phù giác mạc, viêm nội nhãn (nhiễm trùng toàn bộ nhãn cầu), ánh sáng chói và/hoặc quầng sáng đáng kể xung quanh nguồn sáng, máu ở tiền phòng (xuất huyết nội nhãn), mũ tiền phòng (mủ nội nhãn), nhiễm trùng mắt, EVO/EVO+ ICL lệch vị trí, phù hoàng điểm, liệt đồng tử, tăng nhãn áp do nghẽn đồng tử, viêm mắt nặng, viêm mống mắt, viêm màng bồ đào, thoát dịch kính và ghép giác mạc.
Chọn khu vực của bạn
Latin America
Nguồn tham khảo
1Patient Survey, STAAR Surgical ICL Data Registry, 2018
2Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.
3Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
4Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.